Heterocyclic Compounds

Matches 301 - 350 out of 1,016	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/1992/016524A1	BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE There are disclosed certain novel compounds identified as benzo-fused lactams which promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production...
WO/1992/012133A2	ARTHROPODICIDAL CARBOXANILIDES Compounds of formula (I), wherein Q, X, R?1�, R?2�, R?9� and Z are as defined in the text, including compositions containing said compounds and a method for using them to control arthropods.
WO/1992/010485A1	A PROCESS FOR THE PREPARATION OF DILTIAZEM (+)-Cis-3-(acetoxy)-5-[2-(dimethylamino)-ethyl]-2,3-dihydro- 2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one hydrochloride is prepared by N-alkylation of (+)-cis-3-hydroxy-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzot hiazepin-4(5H)-one wi...
WO/1992/005164A1	NOVEL AMINOBENZOSULTAM DERIVATIVES AS LIPOXYGENASE INHIBITORS Aminobenzosultam derivatives as inhibitors of lipoxygenase and useful in the treatment or alleviation of allergic and inflammatory diseases.
WO/1991/017153A1	1,5-BENZOTHIAZEPINONE DERIVATIVES, THEIR PREPARATIONS AND PHARMACEUTICAL USE The invention relates to compounds of general formula (I) and pharmaceutically acceptable salts thereof, to processes for the preparation thereof and pharmaceutical compositions containing them. The new compounds, characterized by the pr...
WO/1991/005549A1	BENZOHETEROCYCLIC COMPOUNDS Novel benzoheterocyclic compounds of formula (I), wherein R?1¿ is H, halogen, alkyl, optionally substituted amino, alkoxy; R?2¿ is H, halogen, alkoxy, phenylalkoxy, OH, alkyl, optionally substituted amino, carbamoyl-alkoxy, optionally ...
WO/1991/000273A1	NEW CYCLIC ANTHRANILIC ACID DERIVATIVE AND METHOD OF PRODUCING THE SAME Cyclic anthranilic acid derivatives of general formula (I) and acid addition salts and alkali salts thereof, useful for treating rheumatism, autoimmune diseases and metabolic bone diseases, wherein R1, R2 and R3 may be the same of differ...
WO/1990/014330A1	NOVEL 8-SUBSTITUTED-2-AMINOTETRALINES A compound of formula (I), where Z is hydrogen or halogen, Q is COR1 or 5- or 6-membered aryl which may contain 1 or 2 heteroatoms selected from N, O or S and may be substituted or fused wherein R is hydrogen or C1-methyl (cis-configurat...
WO/1990/004643A1	PROCESS FOR PREPARING OPTICALLY ACTIVE GLYCIDATE ESTERS This invention relates to a method for the production of (2R,3S)-3-(4-methoxyphenyl)glycidic acids and esters thereof, which are synthetic intermediate for the production of the calcium antagonist diltiazem. The method involves the stere...
WO/1989/012633A1	BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES Vasodilating activity is exhibited by compounds having formula (I), wherein X can be -S- or -CH2-; and R2 is (a), (b), (c), (d), (e), (f), (g), (h), (i) or (j), depending upon the definition of X.
WO/1989/011281A1	METHOD OF AMELIORATING EPILEPTIC SEIZURES A method for ameliorating or preventing generalized tonic-clonic type epileptic seizures in mammals is provided. The method involves systemically administering to a mammal in need of such treatment a compound having formula (I), wherein ...
WO/1989/008643A1	URETHANE-PROTECTED AMINO ACID-N-CARBOXYANHYDRIDES The invention relates to urethane-protected amino acid-N-carboxyanhydride and N-thiocarboxyanhydride compounds which are useful in peptide, polypeptide, and protein synthesis. Disclosed herein is the preparation and use of these novel co...
WO/1989/005806A1	NOVEL ANTIARRHYTHMIC AGENTS III Novel compounds of formula (I), wherein A is a group (a), (b), (c), (d), (e), (f) or (g), useful for the treatment of cardiac arrythmia, pharmaceutical compositions containing such compounds as active ingredients, processes for preparati...
WO/1989/005795A1	NOVEL ANTIARRHYTHMIC AGENTS II Novel compounds of formula (I), wherein A is a group (a), (b), (c), (d), (e), (f), (g), useful for the treatment of cardiac arrythmia, pharmaceutical compositions containing such compounds as active ingredients, processes for preparation...
WO/1989/005794A1	NOVEL ANTIARRHYTHMIC AGENTS I A compound of formula (I) and when appropriate in the form of a racemic mixture or in the form of a stereoisomeric component and the pharmaceutically acceptable salts thereof, in which formula: n is an integer 0, 1 or 2, Y is [CH2]m, CHO...
WO/1987/006934A1	NITRIC ESTERS OF BENZOTHIAZEPINONES Nitric esters of benzothiazepines useful in cardiovascular therapy, and their synthesis methods.
WO/1987/006226A2	AZACYCLOALKANE DERIVATIVES, ABSORPTION PROMOTERS CONTAINING THE DERIVATIVES AS THE EFFECTIVE INGREDIENT AND EXTERNAL PREPARATIONS CONTAINING THE ABSORPTION PROMOTERS An azacycloalkane derivative useful for promoting the absorption of a medicine, an absorption promoting agent comprising at least one of the azacycloalkane derivatives as the effective ingredient for promoting the absorption and an exter...
WO/1987/003782A1	HERBICIDAL ARYL TRIAZOLINONES Herbicidal compounds of formula (I) in which, for example, X is Br, Cl or F; Y is Cl or Br, R2 is CHF2, R3 is CH3, R is lower alkyl and R1 is H, Na, lower alkyl or -SO2R.
WO/1986/000618A1	CONDENSED 7-MEMBERED RING COMPOUNDS AND PROCESS FOR THEIR PREPARATION Novel condensed 7-membered ring compounds represented by formula (I), (wherein R1 and R2 each represents hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxy or, when taken together, they represent tri- or tetramethylene, R3 a...
WO/1985/004657A1	FUSED 7-MEMBERED RING COMPOUNDS AND PROCESS FOR THEIR PREPARATION Novel fused 7-membered ring compounds represented by formula (I), (wherein R1 and R2 each represents hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxy or, when bound to each other, they represent tri- or tetra- methylene, R...
WO/1985/004402A1	FUSED 7-MEMBERED RING COMPOUNDS AND PROCESS FOR THEIR PREPARATION Novel fused 7-membered ring compounds represented by formula (I) wherein R1 and R2 each represents hydrogen, halogen, tri-fluoromethyl, lower alkyl, alkoxy or, when taken together, they represent tri- or tetra-methylene, R3 represents hy...
WO/1985/001730A1	FUSED 7-MEMBERED RING COMPOUNDS AND PROCESS FOR THEIR PREPARATION Novel fused 7-membered ring compounds of formula (I): wherein R1 and R2 each represent hydrogen, halogen, trifluoromethyl, lower alkyl or alkoxy or, when taken together, they represent tri- or tetra-methylene, R3 represents hydrogen, low...
WO/1984/004306A1	FUSED 7-MEMBERED RING COMPOUNDS AND PROCESS FOR THEIR PREPARATION Novel fused 7-membered ring compounds represented by the following formula (I), wherein R1 and R2 each represents hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxy or, when taken together, they represent tri- or tetra-methy...
WO/1984/002704A1	TETRACYCLIC COMPOUNDS Compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein: X is CH2, O, S, or NR where R is C1-4 alkyl; R1 and R2 are independently selected from hydrogen, hydroxy, C1-4 alkyl, C1-4 alkoxy, halogen or CF3; R3 is C1-7...
WO1984002704A2	TETRACYCLIC COMPOUNDS Compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein: X is CH2, O, S, or NR where R is C1-4 alkyl; R1 and R2 are independently selected from hydrogen, hydroxy, C1-4 alkyl, C1-4 alkoxy, halogen or CF3; R3 is C1-7...
WO/1982/002199A1	TRICYCLIC COMPOUNDS New dibenzoxazonine, dibenz-oxazecine or dibenzo-oxaazacycloundecane derivatives and corresponding thia- and aza derivatives thereof, of the general formula I: (FORMULA) or a pharmaceutically acceptable acid addition salt or nitrogen oxi...
JP2024519557A	Potassium channel modulators, compositions and uses Disclosed are compounds having the structure represented by general formula I, stereoisomers thereof, pharmaceutically acceptable salts thereof, or solvates thereof. At the same time, compositions, formulations and uses containing said c...
JP2024512340A	Inhibiting COVID-19 replication with COVID-19 entry inhibitors The present invention relates to compounds, compositions, and methods for treating viral infections. In particular, entry inhibitor compounds are disclosed for the treatment of coronavirus infections, including SARS-CoV-1 and SARS-CoV-2 ...
JP7441199B2	Novel polyolefin catalysts and their uses Disclosed is a new polyolefin catalyst and preparation therefor. Specifically, disclosed is a catalytic system comprising a new complex of iron, cobalt, nickel, palladium, and platinum. In the presence of the catalytic system, oily polye...
JP2024503045A	Crystal forms of ryanodine receptor modulators and their uses The present disclosure describes the use of the compound 4-[(7-methoxy-2,3-dihydro-1, The present invention relates to crystalline forms of 4-benzothiazepine-4(5H)yl)methyl]benzoic acid hemifumarate, pharmaceutical compositions containin...
JP2024500309A	Benzothia(di)azepine compounds and their use as bile acid modulators The present invention relates to certain 1,5-benzothiazepines and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators with apical sodium-dependent bile acid transporter (ASBT) and/or hepatic b...
JP7082861B6	Novel cell-permeable succinate compounds The present invention provides novel cell-permeable succinates and cell permeable precursors of succinate aimed at increasing ATP-production in mitochondria. The main part of ATP produced and utilized in the eukaryotic cell originates fr...
JP7391048B2	Benzothia(di)azepine compounds and their use as bile acid modulators The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (...
JP2023549583A	Drugs for treating ryanodine receptor-related disorders The present disclosure relates to 1,4-benzothiazepine derivatives and their use to treat pathologies associated with ryanodine receptors that control intracellular calcium channel function. [Selection diagram] Figure 1
JP2023537285A	Benzothia(di)azepine compounds and their use as bile acid modulators The present invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators with apical sodium-dependent bile acid transporter (ASBT) and/or hepatic bi...
JP7322048B2	Method for preparing elobixibat The present invention relates to a process for the preparation of certain 1,5-benzothiazepine compounds, and in particular toa process for the preparation of elobixibat. The process can be carried out under mild and safe conditions and m...
JP2023523861A	Salts of neurotherapeutic agents and their uses A salt of a neurotherapeutic agent wherein the neurotherapeutic agent is a substituted benzodiazepine, substituted benzothiazepine, substituted pyridopyrimidine, or substituted amino-cyclohexaneacetic acid and the acid is benzoic acid, n...
JP2023522058A	Benzonitric heterocyclic compound and its preparation and use The present invention discloses benzonitric heterocyclic compounds, methods of making and uses thereof. The present invention provides benzodiazepines of formula I, which can be used as histone deacetylase inhibitors, have selective inhi...
JP2023504645A	Benzothia(di)azepine compounds and their use as bile acid modulators The present invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators with apical sodium-dependent bile acid transporter (ASBT) and/or hepatic bile acid tra...
JP2023504646A	Benzothiazepine compounds and their use as bile acid modulators The present invention relates to 1,5-benzothiazepine derivatives of formula (I). These compounds are bile acid modulators with apical sodium-dependent bile acid transporter (ASBT) and/or hepatic bile acid transport (LBAT) inhibitory acti...
JP2023504647A	Benzothia(di)azepine compounds and their use as bile acid modulators The present invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators with apical sodium-dependent bile acid transporter (ASBT) and/or hepatic bile acid tra...
JP2023504643A	Benzothia(di)azepine compounds and their use as bile acid modulators The present invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators with apical sodium-dependent bile acid transporter (ASBT) and/or hepatic bi...
JP2023001340A	TIANEPTINE OXALATE AND POLYMORPH To provide a method for treating disease.Disclosed herein is an oxalate/co-crystal (tianeptine oxalate) of (RS)-7-(3-chloro-6- methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-ylamino)hep tanoic acid S,S-dioxide (tianeptine) as shown in ...
JP2022116004A	SYNTHESIS METHOD To provide an improved synthesis method of a compound useful in remedy and prevention of a metabolic disorder including diabetes mellitus (I type and II type), and obesity, as well as for prophylaxis of hepatic failure and/or remedy.A co...
JP7094899B2	Synthesis method Methods for the preparation of the following compound are disclosed.The compound can be incorporated into pharmaceutical formulations, including tablets and such tablets can be used for treating cholestatic liver diseases.
JP2022519664A	Benzodiazepine compounds and their use as bile acid modulators The present invention relates to a 1,5-benzothiazepine derivative of formula (I). These compounds are bile acid modulators with apical sodium-dependent bile acid transporters (ASBT) and / or liver bile acid transport (LBAT) inhibitory ac...
JPWO2020145250A1	15-PGDH inhibitor To provide a compound having a 15-PGDH inhibitory action. A compound represented by the general formula (1) or a pharmacologically acceptable salt thereof. [Selection diagram] None
JP2021169519A	NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS To provide novel cell-permeable succinates and cell-permeable precursors of the succinates aimed at increasing ATP production in mitochondria.Provided is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof...
JP2021169518A	NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS To provide novel cell-permeable succinates and cell-permeable precursors of the succinates aimed at increasing ATP production in mitochondria.Provided is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof...
JP6923559B2	Aromatic fluorination method Disclosed is a fluorination method comprising providing an aryl fluorosulfonate and a fluorinating reagent to a reaction mixture; and reacting the aryl fluorosulfonate and the fluorinating reagent to provide a fluorinated aryl species.Al...

Matches 301 - 350 out of 1,016	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >